Highest-materiality recent filing
CONMED appoints two new directors from J&J and Boston Scientific; Board expands to nine
Appointed Celine Martin (ex-J&J MedTech exec) and Jeff Mirviss (ex-Boston Scientific exec) to Board, effective July 1, 2026.
CONMED Q1 2026: GAAP EPS $0.45, adjusted EPS $0.89; raises FY organic revenue growth guidance
Sales $317.0M (-1.3% YoY); domestic -5.8%, international +4.7% as reported.
CONMED names VP & Corporate Controller Andrew Moller as Interim Principal Financial Officer
Andrew Moller, 51, appointed Interim Principal Financial Officer effective March 15, 2026.
CONMED Q4 sales up 7.9%, adjusted EPS $1.43; FY2026 guidance below 2025 adjusted EPS
Q4 sales $373.2M (+7.9% YoY); GAAP EPS $0.54 vs $1.08, adjusted EPS $1.43 vs $1.34.
CONMED provides preliminary 2026 guidance at J.P. Morgan Healthcare Conference; no figures in filing
Presented at J.P. Morgan 44th Annual Healthcare Conference on January 12, 2026.
CONMED CFO Todd Garner to depart; transition to Special Advisor through Nov 2026
Garner's separation effective by Mar 15, 2026 or upon appointment of new CFO; he will serve as Special Advisor until Nov 2, 2026.
CONMED to exit gastroenterology lines; terminates Gore VIABIL agreement effective Jan 1, 2026
Gastroenterology product lines expected to generate $90M–$95M revenue in 2025 with ~45% gross margins.
CONMED Q3 revenue up 6.7% to $338M; adjusted EPS $1.08; suspends dividend, authorizes $150M buyback
Diluted GAAP EPS $0.09 vs $1.57 YoY due to $19.7M product rationalization and $9.2M consulting costs.
CONMED appoints Kim Kelderman to Board of Directors effective Sept 8, 2025
Kim Kelderman appointed to CONMED's Board, effective September 8, 2025.
CONMED declares $0.20 quarterly dividend, payable Oct 3, 2025
Quarterly cash dividend of $0.20 per share declared on August 7, 2025.
CONMED Q2 adj EPS $1.15 beats; raises FY2025 revenue and adj EPS guidance
Q2 sales $342.3M (+3.1% YoY); GAAP EPS $0.69 (down from $0.96), adj EPS $1.15 (up from $0.98).
CONMED director Martha Aronson resigns to become Merit Medical President & CEO
Martha Aronson resigned from CONMED board effective July 7, 2025 to become President and CEO of Merit Medical Systems.
CONMED enters into $750M credit agreement; maturities extended to 2030
New $550M USD revolver, $100M multicurrency revolver, and $100M term loan; maturity date June 10, 2030.
CONMED declares $0.20 dividend; shareholders approve 2025 LTIP and reelect directors
Quarterly cash dividend of $0.20/share declared, payable July 3, 2025 to holders of record June 13, 2025.
On May 19, 2026, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026.
On May 19, 2026, the Board appointed Kimberly Lockwood as Interim Corporate Controller and Interim Principal Accounting Officer of the Company effective June 1, 2026.
On May 19, 2026, the Board of Directors (the “Board”) of CONMED Corporation (the “Company”) increased the size of the Board to nine directors and appointed Celine Martin and Jeff Mirviss as directors, each effective July 1, 2026.
Max materiality 0.75 · Median 0.53 · Most common event leadership